Jafron Biomedical Co., Ltd. Class A

Jafron Biomedical Co., Ltd. Class A

SSZSE:300529
20.14
CNY
-0.08
(-0.40%)
0.83EPS
18.15P/E
12.19BMarket Cap
Mar 26Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.43
0.52
0.72
0.74
0.92
1.29
1.81
2.45
3.33
3.14
2.42
3.43
2.61
2.66
Basic EPS, GAAP
0.18
0.23
0.28
0.27
0.36
0.51
0.72
1.1
1.49
1.12
0.55
1.05
0.69
0.84
Free Cash Flow per Basic Share
0.1
0.1
0.2
0.2
0.16
0.27
0.46
0.75
0.89
0.51
0.84
1.04
0.71
- -
Dividend per Share
0.05
0.12
0.13
- -
0.11
0.19
0.32
0.47
0.66
0.92
0.71
0.44
0.83
0.55
Book Value per Share
1.48
0.64
0.8
1.51
1.76
2.15
2.69
3.51
4.17
4.43
3.9
4.17
4.35
4.57
Tangible Book Value per Share
1.39
0.61
0.77
1.48
1.7
2.03
2.58
3.34
3.99
4.25
3.76
4.04
4.21
4.44
Basic Weighted Avg Shares
709
707
705
739
783
787
793
796
803
794
794
781
772
778
Sales/Revenue/Turnover
304
371
509
544
718
1,017
1,432
1,951
2,675
2,491
1,922
2,677
2,012
2,066
Operating Margin (%)
46.31
45.99
44.77
41.79
40.97
42.7
44.56
51.98
51.67
40.33
27.21
38.98
36.76
41.64
Depreciation Expense
2
4
9
15
16
22
30
37
54
74
95
127
123
- -
Net Income, GAAP
127
160
200
202
284
402
571
875
1,197
890
436
820
533
654
Effective Tax Rate (%)
16.54
16.26
16.42
16.29
16.37
15.26
15.28
15.4
15.02
13.36
18.29
19.14
19.46
16.26
Profit Margin (%)
41.76
43.15
39.39
37.18
39.58
39.55
39.87
44.87
44.73
35.7
22.71
30.63
26.48
31.66
Working Capital
247
257
311
915
961
1,026
1,297
1,651
2,669
2,576
2,482
2,017
2,416
1,750
LT Debt
- -
- -
- -
- -
- -
- -
- -
12
914
954
1,392
1,115
1,187
174
Total Equity
380
452
564
1,184
1,391
1,725
2,171
2,834
3,384
3,590
3,153
3,335
3,471
3,652
Return on Invested Capital (%)
34.45
33.71
36.7
21.64
21.08
25.37
29.09
34.71
32.89
19.19
9.08
17.45
11.62
13.71
Return on Capital (%)
37.79
38.45
38.6
23.12
21.63
25.86
29.41
34.95
33.71
20.28
10.14
18.38
12.24
14.68
Return on Common Equity (%)
37.79
38.45
39.44
23.12
22.09
25.99
29.7
35.37
38.82
25.66
12.99
25.31
15.66
19.32

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
12
1,063
1,126
LT Borrowings
1,225
171
172
LT Finance Leases
4
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
799
799
799
Market Capitalization
14,159
12,299
12,195

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,034
2,789
3,197
Cash, Cash Equivalents & STI
2,632
2,383
2,842
Accounts Receivable, Net
50
46
36
Inventories
257
267
248
Total Current Liabilities
349
1,322
1,448
Payables & Accruals
- -
- -
- -
ST Debt
12
1,063
1,126
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.1%
4.64%
4.1%
Free Cash Flow
22.21%
5.82%
-32.75%
Net Income, GAAP
19.12%
2.6%
-35.04%
Sales/Revenue/Turnover
17.94%
4.37%
-24.86%
Total Cash Common Dividend
- -
20.94%
89.22%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
744
751
700
482
2,677
2025
548
587
- -
456
2,012
2026
561
472
578
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
0.35
0.3
0.04
1.05
2025
0.23
0.26
- -
0.1
0.69
2026
0.28
0.21
0.25
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.42
0.01
0.01
0.44
2025
- -
0.84
- -
- -
0.83
2026
- -
0.54
- -
- -
- -

Company Description

CEO
Fan Dong
Full Time Employees
3,093
Sector
Health technology
Industry
Medical specialties
Address
No. 98 Technology Six Road Zhuhai GD China 519085
IPO Date
Aug 2, 2016
Website
jafron.com
Business
Jafron Biomedical Co.,Ltd. focuses on the development, production, and commercialization of advanced biomaterials and medical devices, particularly within the blood purification and hemoadsorption sectors. The company provides essential solutions for a range of conditions, including kidney and liver diseases, critical illnesses such as sepsis, acute poisoning, and various autoimmune disorders. Their product portfolio encompasses innovative hemoperfusion cartridges, specialized blood purification machines like the DX-10 and Future F20, and adsorption columns targeting bilirubin and immune factors. With a strong emphasis on research and development, Jafron’s proprietary technologies are applied in over 8,000 hospitals across more than 90 countries and regions globally. Established in 1989, the company is headquartered in Zhuhai, China.